RU2013103995A - Диагностика колоректального рака - Google Patents
Диагностика колоректального рака Download PDFInfo
- Publication number
- RU2013103995A RU2013103995A RU2013103995/15A RU2013103995A RU2013103995A RU 2013103995 A RU2013103995 A RU 2013103995A RU 2013103995/15 A RU2013103995/15 A RU 2013103995/15A RU 2013103995 A RU2013103995 A RU 2013103995A RU 2013103995 A RU2013103995 A RU 2013103995A
- Authority
- RU
- Russia
- Prior art keywords
- level
- biomarkers
- colorectal cancer
- mmp
- m2pk
- Prior art date
Links
- 206010009944 Colon cancer Diseases 0.000 title claims abstract 17
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract 17
- 238000003745 diagnosis Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 61
- 239000000090 biomarker Substances 0.000 claims abstract 28
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 claims abstract 9
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 claims abstract 9
- 101710099550 Dickkopf-related protein 3 Proteins 0.000 claims abstract 7
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 claims abstract 7
- 102100040510 Galectin-3-binding protein Human genes 0.000 claims abstract 7
- 101710197901 Galectin-3-binding protein Proteins 0.000 claims abstract 7
- -1 M2PK Proteins 0.000 claims abstract 7
- 230000035945 sensitivity Effects 0.000 claims abstract 7
- 108090000176 Interleukin-13 Proteins 0.000 claims abstract 5
- 108090001007 Interleukin-8 Proteins 0.000 claims abstract 5
- 101150084967 EPCAM gene Proteins 0.000 claims abstract 3
- 102000004890 Interleukin-8 Human genes 0.000 claims abstract 3
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims abstract 3
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims abstract 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims abstract 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims abstract 2
- 102100038778 Amphiregulin Human genes 0.000 claims abstract 2
- 108010033760 Amphiregulin Proteins 0.000 claims abstract 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims abstract 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims abstract 2
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims abstract 2
- 102000001326 Chemokine CCL4 Human genes 0.000 claims abstract 2
- 108010055165 Chemokine CCL4 Proteins 0.000 claims abstract 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims abstract 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims abstract 2
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims abstract 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims abstract 2
- 101000742599 Homo sapiens Vascular endothelial growth factor D Proteins 0.000 claims abstract 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims abstract 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims abstract 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims abstract 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims abstract 2
- 102100037850 Interferon gamma Human genes 0.000 claims abstract 2
- 108010074328 Interferon-gamma Proteins 0.000 claims abstract 2
- 102000003814 Interleukin-10 Human genes 0.000 claims abstract 2
- 108090000174 Interleukin-10 Proteins 0.000 claims abstract 2
- 108090000978 Interleukin-4 Proteins 0.000 claims abstract 2
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract 2
- 102100030417 Matrilysin Human genes 0.000 claims abstract 2
- 108090000855 Matrilysin Proteins 0.000 claims abstract 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims abstract 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims abstract 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims abstract 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims abstract 2
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract 2
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 claims abstract 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims abstract 2
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims abstract 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 claims 1
- 102000013009 Pyruvate Kinase Human genes 0.000 claims 1
- 108020005115 Pyruvate Kinase Proteins 0.000 claims 1
- 102100030416 Stromelysin-1 Human genes 0.000 claims 1
- 101710108790 Stromelysin-1 Proteins 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000001772 blood platelet Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000003608 fece Anatomy 0.000 claims 1
- 210000003593 megakaryocyte Anatomy 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2010903140A AU2010903140A0 (en) | 2010-07-14 | Diagnostic for colorectal cancer | |
| AU2010903140 | 2010-07-14 | ||
| PCT/AU2011/000895 WO2012006681A1 (en) | 2010-07-14 | 2011-07-14 | Diagnostic for colorectal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013103995A true RU2013103995A (ru) | 2014-08-20 |
Family
ID=45468816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013103995/15A RU2013103995A (ru) | 2010-07-14 | 2011-07-14 | Диагностика колоректального рака |
Country Status (13)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011279555B2 (en) * | 2010-07-14 | 2016-10-20 | Vision Tech Bio Pty Ltd | Diagnostic for colorectal cancer |
| US9141756B1 (en) | 2010-07-20 | 2015-09-22 | University Of Southern California | Multi-scale complex systems transdisciplinary analysis of response to therapy |
| CA2825894C (en) | 2011-02-02 | 2021-11-30 | Amgen Inc. | Prognosis of cancer using a circulating biomarker |
| EP2883057B1 (en) * | 2012-08-09 | 2018-12-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Diagnostic of heart failure |
| GB201218341D0 (en) * | 2012-10-12 | 2012-11-28 | Orign Sciences Ltd | Diagnostic method |
| MX2016012697A (es) * | 2014-03-28 | 2017-05-09 | Applied Proteomics Inc | Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales. |
| HUE043951T2 (hu) * | 2014-07-18 | 2019-09-30 | Sanofi Sa | Eljárás rákgyanús beteg aflibercepttel történõ kezelése kimenetének elõrejelzésére |
| CN106191215B (zh) * | 2015-04-29 | 2020-03-24 | 中国科学院上海生命科学研究院 | 肌肉萎缩相关的蛋白质分子标记Dkk-3的筛选及其应用 |
| MY194322A (en) * | 2015-05-12 | 2022-11-28 | Superlab Far East Ltd | Methods of determining interferon having direct inhibitory effects on tumors and uses thereof |
| CN105219844B (zh) * | 2015-06-08 | 2018-12-14 | 华夏京都医疗投资管理有限公司 | 一种筛查十一种疾病的基因标志物组合、试剂盒以及疾病风险预测模型 |
| CN105021828B (zh) * | 2015-07-20 | 2017-07-28 | 上海交通大学医学院附属新华医院 | 通过检测三期结直肠肿瘤患者血清预测肿瘤患者预后 |
| CN105567846A (zh) * | 2016-02-14 | 2016-05-11 | 上海交通大学医学院附属仁济医院 | 检测粪便中细菌dna的试剂盒及其在大肠癌诊断中的应用 |
| JP6984862B2 (ja) * | 2017-03-15 | 2021-12-22 | 国立大学法人金沢大学 | 血中ケモカインをマーカーとして用いた大腸癌の検出 |
| CN107164535A (zh) * | 2017-07-07 | 2017-09-15 | 沈阳宁沪科技有限公司 | 一种无创高通量甲基化结肠癌诊断、研究和治疗方法 |
| CN110540588B (zh) * | 2018-05-28 | 2022-08-23 | 香港中文大学 | 一种基于肿瘤干细胞标志物EpCAM的抗原表位多肽及其应用 |
| CN108957014A (zh) * | 2018-09-27 | 2018-12-07 | 郑州大学第附属医院 | 结直肠癌血清标志物、表达评估方法、试剂盒及应用 |
| JP2022505676A (ja) * | 2018-10-23 | 2022-01-14 | ブラックソーン セラピューティクス インコーポレイテッド | 患者のスクリーニング、診断、及び層別化のためのシステム及び方法 |
| CN109504778B (zh) * | 2019-01-11 | 2021-11-09 | 复旦大学附属中山医院 | 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型 |
| WO2020178172A1 (en) * | 2019-03-01 | 2020-09-10 | Advanced Marker Discovery S.l. | Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof |
| JP7032764B2 (ja) * | 2019-04-03 | 2022-03-09 | 京都府公立大学法人 | 大腸がんの検出方法 |
| JP7300660B2 (ja) * | 2019-04-03 | 2023-06-30 | 京都府公立大学法人 | 大腸がんの検出方法 |
| WO2021097327A1 (en) * | 2019-11-13 | 2021-05-20 | University Of Virginia Patent Foundation | Treatment of clostridium difficile infections |
| EP3835789A1 (en) | 2019-12-13 | 2021-06-16 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Biomarker panel for diagnosing colorectal cancer |
| WO2022130597A1 (ja) * | 2020-12-18 | 2022-06-23 | 国立大学法人東北大学 | 推定装置、推定方法、推定プログラム、生成装置、及び、推定システム |
| JP2024517664A (ja) * | 2021-04-20 | 2024-04-23 | ビジョン・テク・バイオ・プロプライエタリー・リミテッド | 結腸直腸がんのためのバイオマーカー |
| AU2022325178A1 (en) * | 2021-08-11 | 2024-03-28 | Vision Tech Bio Pty Ltd | Method of detecting adenoma |
| WO2023128429A1 (ko) * | 2021-12-31 | 2023-07-06 | 주식회사 이노제닉스 | 대장암 및 진행 선종의 선별 검사 방법 및 그 응용 |
| WO2023128419A1 (ko) * | 2021-12-31 | 2023-07-06 | 주식회사 이노제닉스 | 대장암 및 대장 용종 또는 진행 선종의 선별 방법 및 그 응용 |
| CN114594259B (zh) * | 2022-04-22 | 2022-09-13 | 北京易科拜德科技有限公司 | 一种新型的用于结直肠癌预后预测和诊断的模型及其应用 |
| PL441319A1 (pl) * | 2022-05-31 | 2023-12-04 | Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu | Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro |
| CN119688988A (zh) * | 2024-11-25 | 2025-03-25 | 中国医学科学院肿瘤医院 | Timp1和foxp3作为诊断结直肠癌的生物标志物组合及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
| US20040157278A1 (en) * | 2002-12-13 | 2004-08-12 | Bayer Corporation | Detection methods using TIMP 1 |
| US20050014165A1 (en) * | 2003-07-18 | 2005-01-20 | California Pacific Medical Center | Biomarker panel for colorectal cancer |
| EP2280285A1 (en) * | 2003-09-15 | 2011-02-02 | Oklahoma Medical Research Foundation | Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases |
| BRPI0401830A (pt) | 2004-05-25 | 2006-01-17 | Bentonit Uniao Nordeste Sa | Processo de produção de pós granulados secos |
| ES2427924T3 (es) | 2006-06-30 | 2013-11-04 | Merck Sharp & Dohme Corp. | Biomarcador IGFBP2 |
| US9060961B2 (en) | 2006-11-09 | 2015-06-23 | University Of Washington | Molecules and methods for treatment and detection of cancer |
| US9353415B2 (en) * | 2006-12-19 | 2016-05-31 | Thomson Reuters (Scientific) Llc | Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom |
| CA2676227A1 (en) | 2007-02-12 | 2008-08-21 | The Johns Hopkins University | Early detection and prognosis of colon cancers |
| HUE028487T2 (en) * | 2007-02-27 | 2016-12-28 | Sentoclone Int Ab | Detection of tumor cell multiplex using panel of agents associated with extracellular markers |
| WO2008116178A2 (en) * | 2007-03-21 | 2008-09-25 | Vanderbilt University | Systems and methods for diagnosis and prognosis of colorectal cancer |
| CN101680898A (zh) * | 2007-05-10 | 2010-03-24 | 霍夫曼-拉罗奇有限公司 | Timp-1作为结肠直肠癌标志的用途 |
| EP2145021A2 (en) * | 2007-05-17 | 2010-01-20 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| EP2544006A1 (en) * | 2007-06-04 | 2013-01-09 | Diagnoplex | Biomarker combinations for colorectal cancer |
| US20090017463A1 (en) * | 2007-07-10 | 2009-01-15 | Vanderbilt University | Methods for predicting prostate cancer recurrence |
| EP2271775A4 (en) * | 2008-04-08 | 2011-09-07 | Nuclea Biomarkers Llc | BIOMARKERGROUP FOR PREDICTING THE REPRESENTATION OF COLORECTAL CARCINOMA |
| US20100111969A1 (en) * | 2008-10-31 | 2010-05-06 | Apogenix Gmbh | Il-4 receptor and il-13 as prognostic markers for colon and pancreas tumors |
| AU2009322474A1 (en) * | 2008-12-01 | 2011-07-21 | Lifespan Extension Llc | Methods and compositions for altering health, wellbeing, and lifespan |
| US20110236903A1 (en) * | 2008-12-04 | 2011-09-29 | Mcclelland Michael | Materials and methods for determining diagnosis and prognosis of prostate cancer |
| WO2010096674A2 (en) * | 2009-02-20 | 2010-08-26 | The Regents Of The University Of California | A+ biomarker assays |
| US20110177525A1 (en) * | 2010-01-19 | 2011-07-21 | Predictive Biosciences, Inc. | Antibodies and methods of diagnosing diseases |
| AU2011279555B2 (en) | 2010-07-14 | 2016-10-20 | Vision Tech Bio Pty Ltd | Diagnostic for colorectal cancer |
-
2011
- 2011-07-14 AU AU2011279555A patent/AU2011279555B2/en active Active
- 2011-07-14 ES ES14178981.8T patent/ES2653646T3/es active Active
- 2011-07-14 CN CN201511009181.5A patent/CN105755112B/zh active Active
- 2011-07-14 RU RU2013103995/15A patent/RU2013103995A/ru not_active Application Discontinuation
- 2011-07-14 EP EP14178981.8A patent/EP2829881B1/en active Active
- 2011-07-14 EP EP11806149.8A patent/EP2593795A4/en not_active Withdrawn
- 2011-07-14 IN IN1129CHN2013 patent/IN2013CN01129A/en unknown
- 2011-07-14 PT PT141789818T patent/PT2829881T/pt unknown
- 2011-07-14 WO PCT/AU2011/000895 patent/WO2012006681A1/en active Application Filing
- 2011-07-14 BR BR112013000745-1A patent/BR112013000745B1/pt not_active IP Right Cessation
- 2011-07-14 DK DK14178981.8T patent/DK2829881T3/en active
- 2011-07-14 CN CN201180034158.5A patent/CN103140760B/zh active Active
- 2011-07-14 US US13/809,785 patent/US20130345322A1/en not_active Abandoned
- 2011-07-14 JP JP2013518909A patent/JP6061344B2/ja active Active
- 2011-07-14 NO NO14178981A patent/NO2829881T3/no unknown
-
2017
- 2017-03-28 US US15/471,147 patent/US10877039B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6061344B2 (ja) | 2017-01-18 |
| EP2829881A3 (en) | 2015-05-13 |
| IN2013CN01129A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-07-31 |
| CN103140760B (zh) | 2016-01-27 |
| DK2829881T3 (en) | 2017-12-04 |
| PT2829881T (pt) | 2017-11-29 |
| US10877039B2 (en) | 2020-12-29 |
| EP2593795A1 (en) | 2013-05-22 |
| WO2012006681A1 (en) | 2012-01-19 |
| NO2829881T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2018-01-20 |
| BR112013000745B1 (pt) | 2021-02-02 |
| JP2013533977A (ja) | 2013-08-29 |
| US20130345322A1 (en) | 2013-12-26 |
| CN105755112A (zh) | 2016-07-13 |
| CN105755112B (zh) | 2019-06-07 |
| US20170205414A1 (en) | 2017-07-20 |
| AU2011279555B2 (en) | 2016-10-20 |
| EP2829881B1 (en) | 2017-08-23 |
| EP2593795A4 (en) | 2014-01-22 |
| CN103140760A (zh) | 2013-06-05 |
| ES2653646T3 (es) | 2018-02-08 |
| EP2829881A2 (en) | 2015-01-28 |
| BR112013000745A2 (pt) | 2016-05-24 |
| AU2011279555A1 (en) | 2013-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013103995A (ru) | Диагностика колоректального рака | |
| Shrivastava et al. | Inflammatory markers in patients with rheumatoid arthritis | |
| Yazdan-Ashoori et al. | Elevated plasma matrix metalloproteinases and their tissue inhibitors in patients with severe sepsis | |
| JP2013533977A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| Wu et al. | S 100 A 9, GIF and AAT as potential combinatorial biomarkers in gastric cancer diagnosis and prognosis | |
| CN103898205B (zh) | 半胱氨酸蛋白酶抑制剂sn的应用 | |
| MA33747B1 (fr) | Anticorps monoclonaux diriges contre la progastrine et leurs utilisations | |
| TR201907389T4 (tr) | Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem. | |
| US20140271453A1 (en) | Methods for the early detection of lung cancer | |
| Dong et al. | High levels of TRIM14 are associated with poor prognosis in hepatocellular carcinoma | |
| CN116519954B (zh) | 一种结直肠癌检测模型构建方法、系统及生物标志物 | |
| Molad et al. | Soluble triggering receptor expressed on myeloid cells‐1 is a biomarker of anti‐CCP‐positive, early rheumatoid arthritis | |
| Jeong et al. | Significance of the DNA-histone complex level as a predictor of major adverse cardiovascular events in hemodialysis patients: the effect of uremic toxin on DNA-histone complex formation | |
| Confield et al. | Vibrational spectroscopic analysis of blood for diagnosis of infections and sepsis: a review of requirements for a rapid diagnostic test | |
| JP2015510417A (ja) | 移植可能な装置及びバイオマーカーパネルデータを使用して心不全を診断する方法 | |
| Kushlinskii et al. | Clinical significance of matrix metalloproteinases in blood plasma of patients with gastric cancer | |
| Saichua et al. | Levels of 8-OxodG predict hepatobiliary pathology in Opisthorchis viverrini endemic settings in Thailand | |
| Badanjak | An overview of salivaomics: Oral biomarkers of disease | |
| Toson et al. | Fibrogenic/angiogenic linker for non-invasive assessment of hepatic fibrosis staging in chronic hepatitis C among Egyptian patients | |
| Paulo et al. | Mass spectrometry-based (GeLC-MS/MS) comparative proteomic analysis of endoscopically (ePFT) collected pancreatic and gastroduodenal fluids | |
| Ziloochian et al. | Investigating the relationship between plasma D-Dimer levels and clinical outcomes in COVID-19 patients admitted to Shahid Beheshti hospital in Kashan | |
| ES2932268T3 (es) | Biomarcadores de aterosclerosis subclínica | |
| RU2014154144A (ru) | Аутоиммунные антитела | |
| Venuto et al. | Predicting Cerebrospinal Fluid Alpha-Synuclein Seed Amplification Assay Status from Demographics and Clinical Data | |
| Salih et al. | Salivary matrix metalloproteinase-8 indicate the severity of diabetic foot ulcer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC9A | Changing information about inventors | ||
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170307 |